Vtp-200 Was Generally Well-Tolerated With No Product-Related Serious Adverse Events

Barinthus Biotherapeutics

20/03/2023 12:42

March 20 (Reuters) - Vaccitech PLC  VACC.O :
    * VACCITECH PLC - VTP-200 WAS GENERALLY WELL-TOLERATED WITH
NO
PRODUCT-RELATED SERIOUS ADVERSE EVENTS
    * VACCITECH PLC - VTP-200 WAS GENERALLY WELL-TOLERATED WITH
NO
PRODUCT-RELATED SERIOUS ADVERSE EVENTS
    * VACCITECH PLC - INTERIM DATA SHOWED ENCOURAGING INITIAL
IMMUNOGENICITY RESULTS, PARTICULARLY IN RELATION TO E1, E2 AND
E6 ANTIGENS USED IN VTP-200
    * VACCITECH PLC - HPV001 CLINICAL TRIAL WILL CONTINUE AS
PLANNED
TO 12-MONTH PRIMARY ENDPOINT
    * VACCITECH PLC - LOOK FORWARD TO SEEING FINAL DATA IN EARLY
2024

Source text for Eikon:  ID:nGNX6RVTX5 
Further company coverage:  VACC.O 

 ((Reuters.Briefs@thomsonreuters.com;;))